Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

[Detection and clinical significance of apoptosis related protein in local advanced rectal cancer patients with preoperative neoadjuvant therapy].

Liu Y, Zhang G, Qian J, Zhu YP, Ju HX, Feng HY, Zhu HN, Li DC.

Zhonghua Wai Ke Za Zhi. 2012 Oct;50(10):914-7. Chinese.

PMID:
23302463
2.
3.

Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer.

Tannapfel A, Nüsslein S, Fietkau R, Katalinic A, Köckerling F, Wittekind C.

Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):585-91.

PMID:
9635706
4.

The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.

Edden Y, Wexner SD, Berho M.

Colorectal Dis. 2012 May;14(5):555-61. doi: 10.1111/j.1463-1318.2011.02697.x.

PMID:
21689364
5.

Apoptotic proteins as prognostic markers and indicators of radiochemosensitivity in stage II/III rectal cancers.

Fucini C, Messerini L, Saieva C, Orzalesi L, Carroni V, Bartolini N.

Colorectal Dis. 2012 Feb;14(2):e64-71. doi: 10.1111/j.1463-1318.2011.02763.x.

PMID:
21848899
6.

Expression of Bcl-xL, Bax, and p53 in primary tumors and lymph node metastases in oral squamous cell carcinoma.

Baltaziak M, Duraj E, Koda M, Wincewicz A, Musiatowicz M, Kanczuga-Koda L, Szymanska M, Lesniewicz T, Musiatowicz B.

Ann N Y Acad Sci. 2006 Dec;1090:18-25.

PMID:
17384243
7.

Immunohistochemical assessment of apoptosis-associated proteins: p53, Bcl-xL, Bax and Bak in gastric cancer cells in correlation with clinical and pathomorphological factors.

Gryko M, Pryczynicz A, Guzińska-Ustymowicz K, Kamocki Z, Zaręba K, Kemona A, Kędra B.

Adv Med Sci. 2012 Jun 1;57(1):77-83. doi: 10.2478/v10039-012-0012-z.

PMID:
22440942
8.

Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma.

Chang HJ, Jung KH, Kim DY, Jeong SY, Choi HS, Kim YH, Sohn DK, Yoo BC, Lim SB, Kim DH, Ahn JB, Kim IJ, Kim JM, Yoon WH, Park JG.

Hum Pathol. 2005 Apr;36(4):364-71.

PMID:
15891997
9.

Biopsy specimens obtained 7 days after starting chemoradiotherapy (CRT) provide reliable predictors of response to CRT for rectal cancer.

Suzuki T, Sadahiro S, Tanaka A, Okada K, Kamata H, Kamijo A, Murayama C, Akiba T, Kawada S.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1232-8. doi: 10.1016/j.ijrobp.2012.09.031.

PMID:
23158058
10.

Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer.

Matsumoto H, Wada T, Fukunaga K, Yoshihiro S, Matsuyama H, Naito K.

Jpn J Clin Oncol. 2004 Mar;34(3):124-30.

11.

p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.

Saw RP, Morgan M, Koorey D, Painter D, Findlay M, Stevens G, Clarke S, Chapuis P, Solomon MJ.

Dis Colon Rectum. 2003 Feb;46(2):192-202.

PMID:
12576893
12.

High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection.

Rödel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiss C, Günther K, Schick C, Sauer R, Rödel C.

Strahlenther Onkol. 2002 Aug;178(8):426-35.

PMID:
12240548
14.

Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients' outcome.

Tsamandas AC, Kardamakis D, Petsas T, Zolota V, Vassiliou V, Matatsoris T, Kalofonos H, Vagianos CE, Scopa CD.

In Vivo. 2007 Jan-Feb;21(1):113-8. Erratum in: In Vivo. 2007 May-Jun;21(3):553. Zolota, V [added]; Vassiliou, V [added]; Matatsoris, T [added]. In Vivo. 2007 Nov-Dec;21(6):1172.

15.

Short-term effects of neoadjuvant chemoradiation therapy on anorectal function in rectal cancer patients: a pilot study.

Kye BH, Kim HJ, Kim JG, Kim SH, Shim BY, Lee NS, Cho HM.

Radiat Oncol. 2013 Aug 20;8:203. doi: 10.1186/1748-717X-8-203.

16.

Pretreatment expression of 13 molecular markers as a predictor of tumor responses after neoadjuvant chemoradiation in rectal cancer.

Huh JW, Lee JH, Kim HR.

Ann Surg. 2014 Mar;259(3):508-15. doi: 10.1097/SLA.0b013e31829b3916.

PMID:
23787217
17.

CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.

Wallin U, Rothenberger D, Lowry A, Luepker R, Mellgren A.

Dis Colon Rectum. 2013 Jul;56(7):859-68. doi: 10.1097/DCR.0b013e31828e5a72.

PMID:
23739192
18.

Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients.

Valentini V, Coco C, Picciocchi A, Morganti AG, Trodella L, Ciabattoni A, Cellini F, Barbaro B, Cogliandolo S, Nuzzo G, Doglietto GB, Ambesi-Impiombato F, Cosimelli M.

Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):664-74.

PMID:
12062610
19.

Bcl-XL protein levels determine apoptotic index in pancreatic carcinoma.

Sharma J, Srinivasan R, Majumdar S, Mir S, Radotra BD, Wig JD.

Pancreas. 2005 May;30(4):337-42.

PMID:
15841044
20.

Apoptosis and expression of the Bcl-2 family of proteins and P53 in human pancreatic ductal adenocarcinoma.

Chen D, Zheng X, Kang D, Yan B, Liu X, Gao Y, Zhang K.

Med Princ Pract. 2012;21(1):68-73. doi: 10.1159/000332423.

Items per page

Supplemental Content

Support Center